Contact

VIRTUS RESPIRATORY RESEARCH

Early proof of concept clinical trials.
New therapies for asthma & COPD.
State-of-the-art R&D.

Virtus can assist in the development of new treatments for asthma and COPD

Learn more

Virtus’s range of in vitro and in vivo pre-clinical models

Learn more

Human Studies

Learn more

Meet the Virtus team

Learn more

Participate in one of our clinical trials

Learn more

Virtus team publication track record

Learn more

OUR SERVICES

We perform pre-clinical and clinical research studies in respiratory infections and airway diseases...

FIND OUT MORE

Latest from Virtus

#ERSCongress - Precision meets immunology. Nice talk by Prof. Pavord showing that dupilumab reduces AE most impressively in high FeNO, high eos T2 asthmatics.

Could this be restoration of impaired anti-viral immunity?
See

#VirTus

#ERSCongress – Hot topics: microbiome, infection and host defence. Prof Smits discusses parasites, microbiota and their influence on the immune system.

Is H. polygyrus the next source of T2 cytokine blockers? Watch this space.

#ERS2019 #Asthma #VirTus #ERSTalks

#ERSCongress – In beyond T2 mechanisms in asthma, phages as magic bullets Prof J Simpson: surely the lung immune response is not aimed solely at bacteria but the phages they contain? Phages as a source of inflammation?

#ERS2019 #Asthma #Inflammation #VirTus

#ERSCongress – In beyond T2 mechanisms in asthma, phages as magic bullets by Prof. J Simpson.
Are we heading towards mapping out the respiratory phagome?
#ERS2019 #Asthma #VirTus

#ERSCongress It takes 2 to tango: Prof Nair interesting talk on T cell biology and eos; TH2 cells remain an elusive target. Also, a great overview of potential importance of DR3/TL1a signalling in ILC2 and eosinophilia crosstalk. Surely the next big target in T2 asthma!
#ERSTalks

#ERSCongress – It takes 2 to tango: Prof HJ Hoffmann gave a great talk on IgE mast cell interactions and possible implications for asthma severity.

#ERS2019 #Asthma #VirTus #ERSTalks

#ERSCongress – It takes 2 to tango: Prof P Bradding discussion on the effects of SABAs on mast cell function. Shows how little we know about the immunomodulatory effects of beta2agonists, both harmful and beneficial.

#ERS2019 #Asthma #COPD #VirTus

#ERSCongress – New recommendations and priorities for asthma management: Prof @Sebastian Johnston gives keynote speech on the risk of asthma deaths and beta-2-agonist overuse.

#ERS2019 #Asthma #VirTus #ERSTalks

More Tweets

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Our clients

We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.

The email address is incorrect
Please agree to our Privacy and Policy
Something went wrong